Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06504524 · MORE INFO

Limitations, agreements, and source contact

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US · Source last updated 2025-06-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
There were some limitations of the study resulting in poor overlap between study arms suggesting that groups are not well comparable in terms of the observed confounding characteristics used for adjustment. This should be taken into consideration when interpreting results.
point Of Contact
email
ClinicalTrials.gov_Inquiries@pfizer.com
organization
Pfizer Inc.
phone
1-800-718-1021
title
Pfizer ClinicalTrials.gov Call Center
Complete source fields
certain Agreement
other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
There were some limitations of the study resulting in poor overlap between study arms suggesting that groups are not well comparable in terms of the observed confounding characteristics used for adjustment. This should be taken into consideration when interpreting results.
point Of Contact
email
ClinicalTrials.gov_Inquiries@pfizer.com
organization
Pfizer Inc.
phone
1-800-718-1021
title
Pfizer ClinicalTrials.gov Call Center

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice